Developing treatment of symmetrical peripheral neuropathy involving mitochondrial injury
| Project/Area Number |
16K10985
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Anesthesiology
|
|---|
| Research Institution | Jikei University School of Medicine |
|---|
Principal Investigator |
Shimoyama Megumi 東京慈恵会医科大学, 医学部, 非常勤講師 (10206253)
|
|---|
| Project Period (FY) |
2016-04-01 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Keywords | 化学療法惹起性神経障害 / ミトコンドリア障害 / オキサリプラチン / パクリタキセル / SS-20 / 化学療法惹起性末梢神経障害 / 表皮内神経線維 / 神経障害性疼痛 / ミトコンドリア / 末梢神経障害 / 疼痛 |
|---|
| Outline of Final Research Achievements |
We showed that SS-20, a newly developed compound that possesses mitochondrial protective properties, can prevent the development of peripheral neuropathies in mice induced by oxaliplatin and paclitaxel, both widely used chemotherapy agents to treat cancer patients. These results suggest that peripheral neuropathies induced by multiple chemotherapy agents likely possess a common mechanism, i.e. mitochondrial injury. Furthermore, these results suggest that SS-20 may be a promising candidate for the prevention of chemotherapy-induced peripheral neuropathy.
|
| Academic Significance and Societal Importance of the Research Achievements |
がん治療で広く用いられているオキサリプラチンやパクリタキセルの重大な副作用である末梢神経障害は予防法が確立されておらず、症状緩和も困難で、がん治療を困難にする要因となっている。本研究の成果はミトコンドリア障害に焦点を当て、化学療法惹起性末梢神経障害の予防法の開発に貢献するものと考えられる。
|
Report
(8 results)
Research Products
(18 results)
